The UK Divide: Does Having a Pembrolizumab–Chemotherapy Option in Head and Neck Cancer Matter? Real-world Experience of First-line Palliative Pembrolizumab Monotherapy and Pembrolizumab–Chemotherapy Combination in Scotland
-
Published:2024-05
Issue:5
Volume:36
Page:287-299
-
ISSN:0936-6555
-
Container-title:Clinical Oncology
-
language:en
-
Short-container-title:Clinical Oncology
Author:
Thapa A.ORCID,
Cowell A.ORCID,
Peters A.ORCID,
Noble D.J.ORCID,
James A.ORCID,
Lamb C.,
Grose D.,
Vohra S.,
Schipani S.ORCID,
Mactier K.ORCID,
Mackenzie J.ORCID,
Srinivasan D.,
Laws K.ORCID,
Moleron R.ORCID,
Niblock P.,
Soh F.-Y.,
Paterson C.ORCID,
Wilson C.ORCID
Reference30 articles.
1. Head and neck cancer in the UK: what was the stage before COVID-19? UK cancer registries analysis (2011–2018);Creaney;Br Dent J,2022
2. Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Machiels;Ann Oncol,2020
3. Cancer survival statistics - people diagnosed with cancer during 2015 to 2019,2022
4. A guide to cancer immunotherapy: from T cell basic science to clinical practice;Waldman;Nat Rev Immunol,2020
5. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study;Burtness;Lancet,2019
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献